Low anterior resection syndrome after low anterior resection for rectal cancer research hub

A randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and quality of life outcomes of Vi-Siblin in patients with low anterior resection syndrome following rectal cancer surgery.

This study looks at whether a fibre supplement called Vi-Siblin can help people who have bowel problems (Low Anterior Resection Syndrome, or LARS) after surgery for rectal cancer. It compares Vi-Siblin to a dummy powder to see if it improves symptoms and quality of life.